<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091022</url>
  </required_header>
  <id_info>
    <org_study_id>pending new</org_study_id>
    <secondary_id>R01CA193885</secondary_id>
    <nct_id>NCT04091022</nct_id>
  </id_info>
  <brief_title>Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Phase II Chemoprevention Clinical Trial of Topical Diclofenac and DFMO in Subjects With a History of Skin Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single institution, randomized, placebo-controlled, double-blind phase IIB trial of&#xD;
      1) topical diclofenac and topical DFMO, or 2) placebo in participants with a history of non&#xD;
      melanoma skin cancer/ keratinocytic cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be two groups to the study. Individuals, aged 18 years or older, who have&#xD;
      extensive actinic damage, at least 8 AKs and a history of at least one non-melanoma skin&#xD;
      cancer, but are in otherwise general good health, will be given topical diclofenac and&#xD;
      topical DFMO. They will be compared to individuals, aged 18 years or older, who have&#xD;
      extensive actinic damage, but are in otherwise general good health, will be given placebo.&#xD;
      All participants must be at increased risk of non-melanoma skin cancer as evidenced by a&#xD;
      history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses,&#xD;
      and the presence, at baseline, of at least eight actinic keratoses on the face, neck, scalp&#xD;
      and arms. Subjects will be randomized to:&#xD;
&#xD;
        1. topical diclofenac twice daily and topical DFMO daily&#xD;
&#xD;
        2. placebo for the topical diclofenac BID and placebo for the topical DFMO daily&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This trial will be double-blinded. The clinical team and patient will remain blinded to the randomization.&#xD;
All study drug will be blinded except to the pharmacists. Records will be kept to document receipt, distribution and disposition of the drugs. Unblinding will only be done at the end of the study or as medically indicated with consent of the study PI and the biostatistician, after consulting the NIH Project Officer.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in incidence of non-melanoma skin cancer</measure>
    <time_frame>one year</time_frame>
    <description>The purpose of the study is to determine whether participants randomized to a combination of two FDA approved topical medications topical diclofenac and topical DFMO have a significant change in incidence of (≥ 50% change, p ≤ 0.05) non-melanoma skin cancers (NMSC) than participants randomized to placebo as assessed by clinical and histopathological evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>one year</time_frame>
    <description>Determination of safety of the combination of topical diclofenac and topical DFMO as compared to placebo using the NCI- Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker assessment</measure>
    <time_frame>one year</time_frame>
    <description>To assess the effect of topical diclofenac and topical DFMO on the following biomarkers in biopsied non-sun exposed skin, skin tissue that has chronic sun damage, and in actinic keratosis skin lesions at 0 and 9 months:&#xD;
mRNA expression of Sonic Hedgehog, Hip1, Ptch1, Gli1, Gli2, Gli3, and p53, Prostaglandin E2, Proliferation indices (PCNA, cyclin D1), Apoptosis markers (Tunel staining, Bcl-2, caspase-3), Polyamine concentrations (putrescine, spermidine, spermine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker assessment of NMSC</measure>
    <time_frame>one year</time_frame>
    <description>Effect of topical diclofenac and topical DFMO on biomarkers of squamous cell skin cancer and basal cell skin cancer which include mRNA expression of p53,proliferation indices (PCNA, cyclin D1),apoptosis markers (Tunel staining, Bcl-2, caspase-3), andmarkers of epithelial adhesion (E-cadherin)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Non-melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Diclofenac + DFMO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will apply topical diclofenac to bilateral forearms twice per day and topical DFMO to bilateral forearms once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will apply placebo for topical diclofenac to bilateral forearms twice per day and placebo for topical DFMO to bilateral forearms once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solaraze and Vaniqa</intervention_name>
    <description>Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for one year</description>
    <arm_group_label>Diclofenac + DFMO</arm_group_label>
    <arm_group_label>Placebo + placebo</arm_group_label>
    <other_name>Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  · Previous treatment for basal or squamous cell skin cancer stage 0-2 and current&#xD;
             evidence of actinic keratosis on the upper extremities (upper arms, forearms and&#xD;
             hands), neck, face or scalp.&#xD;
&#xD;
               -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
               -  ECOG performance status 0-1&#xD;
&#xD;
               -  Willing and able to participate for the full duration of the study&#xD;
&#xD;
               -  Greater than 4 weeks from:&#xD;
&#xD;
               -  Prior major surgery for any indication&#xD;
&#xD;
               -  Prior chemotherapy, hormonal therapy or radiation therapy for cancer&#xD;
&#xD;
               -  Willing to abstain from:&#xD;
&#xD;
          -  The application of topical medications including prescription and over the counter&#xD;
             preparations (e.g. Topical preparations containing corticosteroids or vitamin A&#xD;
             derivatives) to areas of actinic damage for the duration of the study. Use of&#xD;
             moisturizers/emollients and sunscreens on these areas is allowed.&#xD;
&#xD;
          -  Chronic (defined as &gt; 3 times/week for more than 2 consecutive weeks/year) NSAID and&#xD;
             COX-2 inhibitor use (other than cardioprotective doses of aspirin &lt; 100 mg po QD) for&#xD;
             the duration of the study. For routine analgesia, subjects may take acetaminophen as&#xD;
             necessary.&#xD;
&#xD;
               -  Normal organ and marrow function defined as laboratory values falling within the&#xD;
                  specified ranges for the following tests (performed within 31 days of&#xD;
                  registration)&#xD;
&#xD;
               -  Hematologic&#xD;
&#xD;
                    -  WBC &gt;3,000/ul&#xD;
&#xD;
                    -  Hemoglobin &gt; lower limit of normal&#xD;
&#xD;
                    -  Platelet count &gt; 100,000/ul&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Total bilirubin &lt; 1.5 X ULN&#xD;
&#xD;
                    -  AST (SGOT) &lt; 1.5 X ULN&#xD;
&#xD;
                    -  ALT (SPGT) &lt; 1.5 X ULN&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Serum creatinine &lt; 1.5 X ULN&#xD;
&#xD;
                    -  BUN &lt; 1.5 X ULN&#xD;
&#xD;
               -  Females of childbearing potential must:&#xD;
&#xD;
                    -  Have been using adequate contraception (abstinence, IUD, birth control pills&#xD;
                       or spermicidal gel with diaphragm or condom) since their last menses&#xD;
&#xD;
                    -  Have a documented negative serum pregnancy test within 14 days prior to the&#xD;
                       first dose of study medication&#xD;
&#xD;
        FEMALES ARE NOT CONSIDERED TO BE OF CHILDBEARING POTENTIAL IF THEY ARE AT LEAST 1 YEAR&#xD;
        POST-MENOPAUSAL OR HAVE HAD A TUBAL LIGATION, BILATERAL OOPHORECTOMY OR HYSTERECTOMY.&#xD;
&#xD;
        · The effects of DFMO and diclofenac on the developing fetus are unknown. Therefore, all&#xD;
        females of childbearing potential and all men capable of fathering a child must agree to&#xD;
        use adequate contraception (abstinence, IUD, birth control pills, or spermicidal gel with&#xD;
        diaphragm or condom) for the duration of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Within 3 months prior to randomization:&#xD;
&#xD;
          -  Use of oral or intravenous corticosteroids for more than 2 consecutive weeks&#xD;
&#xD;
          -  Use of inhaled corticosteroids for more than 4 consecutive weeks&#xD;
&#xD;
             · Any of the following in the 4 weeks (or as indicated) prior to randomization:&#xD;
&#xD;
          -  Major surgery for any indication&#xD;
&#xD;
          -  Cytotoxic chemotherapy for any indication (including methotrexate for arthritis)&#xD;
&#xD;
          -  Anti-cancer treatment of any type other than for a stage 0-2 non-melanoma skin cancer&#xD;
&#xD;
          -  Hormonal therapy for cancer prevention (including tamoxifen) Note: treatment with&#xD;
             finasteride/dutasteride for BPH does not render a participant ineligible.&#xD;
&#xD;
          -  Radiation therapy&#xD;
&#xD;
          -  Topical medications for the treatment of actinic keratosis or skin cancer (etretinate,&#xD;
             5-FU, imiquimod, ingenol) in the 6 months prior to randomization.&#xD;
&#xD;
          -  Laser resurfacing, dermabrasion, cryotherapy, chemical peel and electrodissection ±&#xD;
             curettage in the 6 months prior to randomization.&#xD;
&#xD;
          -  Aspirin (&gt;100 mg/day) - Note: cardioprotective doses (&lt; 100mg/day) are acceptable.&#xD;
&#xD;
          -  NSAIDs (other than aspirin &lt; 100mg/day) or COX-2 inhibitors &gt; 3 times/week for more&#xD;
             than a two week period&#xD;
&#xD;
          -  Topical steroids&#xD;
&#xD;
               -  Any personal history of:&#xD;
&#xD;
                    -  Invasive cancer diagnosed or treated within the past 5 years. Participants&#xD;
                       who have been in remission for 5 years or more and have not required&#xD;
                       treatment in the past 5 years may be eligible if a study chair or principal&#xD;
                       investigator believes there is little to no risk of recurrence.&#xD;
&#xD;
                    -  Solid organ or bone marrow transplant&#xD;
&#xD;
                    -  Biopsy proven hepatic cirrhosis&#xD;
&#xD;
                    -  Keloid formation&#xD;
&#xD;
                    -  Photosensitivity disorder&#xD;
&#xD;
                    -  Hypersensitivity or adverse reactions to nonsteroidal anti-inflammatory&#xD;
                       agents&#xD;
&#xD;
                    -  Oral DFMO for &gt; 1 month on a prior study&#xD;
&#xD;
                    -  Any disease that predisposes to NMSC&#xD;
&#xD;
                    -  An immunodeficiency disorder or the use of an immunosuppressive drug&#xD;
&#xD;
               -  Any family history of&#xD;
&#xD;
                  o Ornithine diaminotransferase deficiency in a first degree relative&#xD;
&#xD;
               -  Concurrent use of the following medications or treatments&#xD;
&#xD;
                    -  Systemic therapy with psoralens, immunotherapy, retinoids, or radiation&#xD;
                       therapy&#xD;
&#xD;
                    -  Cytotoxic chemotherapy for any reason (including methotrexate for arthritis)&#xD;
&#xD;
                    -  Topical or systemic immunosuppressive therapy.&#xD;
&#xD;
               -  Females who are pregnant or lactating. Should a woman become pregnant or suspect&#xD;
                  she is pregnant while she is participating in this study she should notify her&#xD;
                  study physician immediately.&#xD;
&#xD;
               -  Uncontrolled concurrent illness including ongoing or active infection,&#xD;
                  symptomatic congestive heart failure, unstable angina pectoris, uncontrolled&#xD;
                  symptomatic cardiac arrhythmia, psychiatric illness/social situations that would&#xD;
                  limit compliance with study requirements or other underlying serious medical&#xD;
                  condition which, in the investigator's opinion might preclude study&#xD;
                  participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craug Elmets, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Saag, CRNP</last_name>
    <phone>205-996-6589</phone>
    <email>lsaag@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Elmets, MD</last_name>
    <phone>205-934-5188</phone>
    <email>celmets@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Dermatology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralee Bunt</last_name>
      <phone>256-375-9457</phone>
      <email>erikabunt@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mona Reeves</last_name>
      <phone>205-502-9661</phone>
      <email>rreeves@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Craig Elmets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Whitaker Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralee Bunt</last_name>
      <phone>256-375-9457</phone>
      <email>erikabunt@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Elmets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Craig Elmets</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>topical chemoprevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

